IN2014CN02680A - - Google Patents

Info

Publication number
IN2014CN02680A
IN2014CN02680A IN2680CHN2014A IN2014CN02680A IN 2014CN02680 A IN2014CN02680 A IN 2014CN02680A IN 2680CHN2014 A IN2680CHN2014 A IN 2680CHN2014A IN 2014CN02680 A IN2014CN02680 A IN 2014CN02680A
Authority
IN
India
Prior art keywords
membered
1compound
mixtures
indicates
preventing
Prior art date
Application number
Other languages
English (en)
Inventor
Yoram Kapulnik
Hinanit Koltai
Ronit Yarden
Cristina Prandi
Original Assignee
Israel State
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Israel State, Univ Georgetown filed Critical Israel State
Publication of IN2014CN02680A publication Critical patent/IN2014CN02680A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN2680CHN2014 2011-09-21 2012-09-20 IN2014CN02680A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161537062P 2011-09-21 2011-09-21
US201261614965P 2012-03-23 2012-03-23
PCT/IL2012/050381 WO2013042124A1 (en) 2011-09-21 2012-09-20 Use of strigolactones and strigolactone analogs for treating proliferative conditions

Publications (1)

Publication Number Publication Date
IN2014CN02680A true IN2014CN02680A (cg-RX-API-DMAC7.html) 2015-07-03

Family

ID=47913975

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2680CHN2014 IN2014CN02680A (cg-RX-API-DMAC7.html) 2011-09-21 2012-09-20

Country Status (7)

Country Link
US (1) US10208007B2 (cg-RX-API-DMAC7.html)
EP (1) EP2758392B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014527979A (cg-RX-API-DMAC7.html)
CN (1) CN104053655A (cg-RX-API-DMAC7.html)
CA (1) CA2849343C (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02680A (cg-RX-API-DMAC7.html)
WO (1) WO2013042124A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458154B2 (en) 2013-09-06 2022-10-04 Vanda Pharmaceuticals Inc. Treatment of CYR61- and VEGF-mediated conditions
US20180235213A1 (en) * 2015-05-14 2018-08-23 The State of Israel Ministry of Agriculture & Rural Develop. Agricultural Research Organization Plant hormone application
GB201615544D0 (en) * 2016-09-13 2016-10-26 Syngenta Participations Ag Plant Growth regulator compounds
CN108558796B (zh) * 2018-05-07 2020-04-07 南开大学 一类羟亚甲基氢化茚酮衍生物及其制备方法和用途
CN108675974B (zh) * 2018-05-07 2020-04-07 南开大学 一类独脚金内酯衍生物及其制备方法和用途
EP3876927A1 (en) * 2018-11-08 2021-09-15 Universita' Degli Studi di Torino Strigolactones for use in preventing and/or treating infections caused by viruses of the herpesviridae family
CN117843651B (zh) * 2024-01-03 2024-09-10 盐城工学院 一种含有三氟甲基季碳中心的四氢呋喃并[3,2-b]吲哚啉类化合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865897B1 (fr) 2004-02-10 2006-06-09 Univ Toulouse Modulateurs de developpement des champignons mycorhiziens a arbuscules, et applications.
TW200904330A (en) 2007-06-15 2009-02-01 Bayer Cropscience Sa Pesticidal composition comprising a strigolactone derivative and a fungicide compound
TW200904331A (en) 2007-06-15 2009-02-01 Bayer Cropscience Sa Pesticidal composition comprising a strigolactone derivative and an insecticide compound
EP2248421A1 (en) 2009-05-07 2010-11-10 GMI - Gregor-Mendel-Institut für Molekulare Pflanzenbiologie GmbH Accumulation of biomass in plants
FI20106119A0 (fi) 2010-10-27 2010-10-27 Sirtuin Valley Oy Energia-aineenvaihduntaan vaikuttava koostumus

Also Published As

Publication number Publication date
CA2849343A1 (en) 2013-03-28
CN104053655A (zh) 2014-09-17
US10208007B2 (en) 2019-02-19
EP2758392B1 (en) 2019-09-18
EP2758392A4 (en) 2015-05-20
EP2758392A1 (en) 2014-07-30
US20140323563A1 (en) 2014-10-30
CA2849343C (en) 2020-12-15
WO2013042124A8 (en) 2013-07-25
WO2013042124A1 (en) 2013-03-28
JP2014527979A (ja) 2014-10-23

Similar Documents

Publication Publication Date Title
IN2014CN02680A (cg-RX-API-DMAC7.html)
UY39630A (es) Inhibidores de bromodominios
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MY196383A (en) Benzo[B]Thiophene Compounds As Sting Agonists
MX2019003468A (es) Derivados de tieno [3,2-d]pirimidina que tienen actividad inhibidora de las cinasas de proteina.
PH12016500024A1 (en) Bromodomain inhibitor
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX394360B (es) Inhibidores de jak2 y alk2 y metodos para su uso.
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
PH12013502112A1 (en) Amide compound and pharmaceutical application therefor
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
TN2012000533A1 (en) New forms of rifaximin and uses thereof
DOP2014000081A (es) Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
IN2014DN06869A (cg-RX-API-DMAC7.html)
WO2014062838A3 (en) Pkm2 modulators and methods for their use
PH12015501386A1 (en) Tricyclic compounds
MX373389B (es) Derivado de sulfonamida y uso farmaceutico del mismo.
WO2014153495A9 (en) Novel stat3 inhibitors
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
DOP2013000305A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
MY173564A (en) Cxcr7 receptor modulators
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
MX368635B (es) Compuestos tricíclicos de piperidina.